Clinical management of inflammatory bowel disease from preconception to postpartum.

IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Loren G Rabinowitz, Ajay Gade, Tina Deyhim, Alessandra Saraga, Joseph D Feuerstein
{"title":"Clinical management of inflammatory bowel disease from preconception to postpartum.","authors":"Loren G Rabinowitz, Ajay Gade, Tina Deyhim, Alessandra Saraga, Joseph D Feuerstein","doi":"10.1080/17474124.2025.2577985","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, often affects individuals during their peak reproductive years. Female patients with IBD face unique challenges across the reproductive years, from fertility and conception to delivery and lactation. Despite increasing awareness, knowledge gaps remain regarding optimal management during pregnancy and postpartum. This review outlines these challenges and provides a practical, evidence-based approach across reproductive stages.</p><p><strong>Areas covered: </strong>This review summarizes care for IBD in reproductive years, including preconception counseling, pregnancy management, delivery planning, surgical and perianal disease considerations, postpartum care, breastfeeding, and infant vaccination after biologic exposure.</p><p><strong>Expert opinion: </strong>Managing IBD from preconception through the postpartum period requires early planning, multidisciplinary coordination, and patient-centered care. Disease remission is the strongest predictor of maternal and fetal outcomes. Most IBD therapies, including biologics, are safe in pregnancy and lactation and should continue, except small molecules, which remain contraindicated due to teratogenic risk or limited safety data. Rotavirus and other vaccinations can generally be administered on schedule in infants exposed to biologics in utero. A proactive, treat-to-target strategy throughout pregnancy, combined with close postpartum monitoring, can prevent disease flares and support optimal outcomes for both mother and child.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2025.2577985","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, often affects individuals during their peak reproductive years. Female patients with IBD face unique challenges across the reproductive years, from fertility and conception to delivery and lactation. Despite increasing awareness, knowledge gaps remain regarding optimal management during pregnancy and postpartum. This review outlines these challenges and provides a practical, evidence-based approach across reproductive stages.

Areas covered: This review summarizes care for IBD in reproductive years, including preconception counseling, pregnancy management, delivery planning, surgical and perianal disease considerations, postpartum care, breastfeeding, and infant vaccination after biologic exposure.

Expert opinion: Managing IBD from preconception through the postpartum period requires early planning, multidisciplinary coordination, and patient-centered care. Disease remission is the strongest predictor of maternal and fetal outcomes. Most IBD therapies, including biologics, are safe in pregnancy and lactation and should continue, except small molecules, which remain contraindicated due to teratogenic risk or limited safety data. Rotavirus and other vaccinations can generally be administered on schedule in infants exposed to biologics in utero. A proactive, treat-to-target strategy throughout pregnancy, combined with close postpartum monitoring, can prevent disease flares and support optimal outcomes for both mother and child.

从孕前到产后炎症性肠病的临床处理。
简介:炎症性肠病(IBD),包括克罗恩病和溃疡性结肠炎,通常影响个体的生育高峰期。女性IBD患者在生育期面临着独特的挑战,从生育和受孕到分娩和哺乳。尽管提高了认识,但关于妊娠和产后最佳管理的知识差距仍然存在。本综述概述了这些挑战,并提供了一种实用的、基于证据的跨生殖阶段方法。涵盖领域:本综述总结了育龄期IBD的护理,包括孕前咨询、妊娠管理、分娩计划、手术和肛周疾病的考虑、产后护理、母乳喂养和生物暴露后的婴儿疫苗接种。专家意见:从孕前到产后管理IBD需要早期规划、多学科协调和以患者为中心的护理。疾病缓解是孕产妇和胎儿预后的最强预测因子。大多数IBD治疗,包括生物制剂,在妊娠和哺乳期是安全的,应该继续使用,除了小分子,由于致畸风险或有限的安全性数据仍然是禁忌。轮状病毒和其他疫苗接种一般可在子宫内暴露于生物制剂的婴儿按计划进行。在整个怀孕期间采取积极主动、从治疗到目标的策略,并结合密切的产后监测,可以预防疾病发作,并支持母亲和孩子的最佳结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Gastroenterology & Hepatology
Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
6.80
自引率
2.60%
发文量
86
审稿时长
6-12 weeks
期刊介绍: The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信